Frazier Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Frazier Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-105,144	Closed	-$691K	–	38
2020 Q3	$691K	Hold	105,144	–	–	0.06%	30
2020 Q2	$781K	Hold	105,144	–	–	0.07%	26
2020 Q1	$495K	Hold	105,144	–	–	0.06%	25
2019 Q4	$1.36M	Hold	105,144	–	–	0.23%	19
2019 Q3	$1.1M	Hold	105,144	–	–	0.35%	18
2019 Q2	$1.79M	Hold	105,144	–	–	0.46%	18
2019 Q1	$3.54M	Hold	105,144	–	–	0.85%	16
2018 Q4	$3.07M	Hold	105,144	–	–	0.79%	17
2018 Q3	$6.48M	Hold	105,144	–	–	1.19%	14
2018 Q2	$7.76M	Buy	+105,144	New	+$8.2M	1.61%	11

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Frazier Management's BLCM Position: Q4 2020 in Review

Frazier Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2020, closing a stake of 105,144 shares — an estimated $691K sold.

Frazier Management first reported a position in BLCM in Q2 2018 and held it in 10 quarters. The position peaked at $7.76M in Q2 2018. 34 funds tracked by Wall St. Rank hold BLCM as of Q4 2020.

Frazier Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Frazier Management sold 105,144 Bellicum Pharmaceuticals, Inc. shares in Q4 2020, an estimated $691K.
Frazier Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 10 quarters.
Frazier Management's Bellicum Pharmaceuticals, Inc. position peaked at $7.76M in Q2 2018.
34 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2020.

Based on Frazier Management's 13F filing for Q4 2020, filed 11 Feb 2021.